The FDA approved Cytokinetics’ Myqorzo to treat obstructive hypertrophic cardiomyopathy, giving the company its first U.S. drug approval after decades of development. Myqorzo will launch commercially in late January; Cytokinetics will compete directly with an existing Bristol Myers Squibb product approved in 2022. The approval marks a milestone for the company’s transition from R&D-stage biotech to commercial supplier and reshapes competitive dynamics in a relatively small rare‑disease cardiology market.